An epidemiologic risk prediction model for ovarian cancer in Europe: The EPIC study

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1257-1265

  Li, K ^a   Husing A ^a   Fortner, R T ^a   Tjonneland A ^b   Hansen, L ^b   Dossus, L ^c,d   Chang Claude, J ^a   Bergmann, M ^e   Steffen, A ^e   Bamia, C ^f   Trichopoulos, D ^g,h,i   Trichopoulou, A ^h,i   Palli, D ^j   Mattiello, A ^k   Agnoli, C ^l   Tumino, R ^m   Onland Moret, N C ⁿ   Peeters, P H ^n,o   Bueno de Mesquita, H B ^p   Gram, I T ^q   Weiderpass, E ^q,r,s   Sanchez Cantalejo E ^t,u   Chirlaque, M D ^u,v   Duell, E J ^w   Ardanaz, E ^u,x   Idahl, A ^y   Lundin, E ^y   Khaw, K T ^z   Travis, R C ^aa   Merritt, M A ^o   Gunter, M J ^o   Riboli, E ^o   Ferrari, P ^ab   Terry, K ^g,ac   Cramer, D ^g,ac   Kaaks, R ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h BIOMEDICAL RESEARCH FOUNDATION   (Greece)

ⁱ HELLENIC HEALTH FOUNDATION   (Greece)

^j CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m CIVILE M P AREZZO HOSPITAL   (Italy)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^q UNIVERSITY OF TROMSØ   (Norway)

^r CANCER REGISTRY OF NORWAY   (Norway)

^s KAROLINSKA INSTITUTE   (Sweden)

^t ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^u CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^v Murcia Regional Health Authority   (Spain)

^w BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^x INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^y UMEÅ UNIVERSITY   (Sweden)

^z UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^aa UNIVERSITY OF OXFORD   (United Kingdom)

^ab INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ac BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Ovarian cancer; Reproductive risk factors; Risk model

Indexed keywords

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CANCER RISK; CLINICAL ASSESSMENT; DISEASE DURATION; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDY; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY CANCER; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; CLINICAL TRIAL; COHORT ANALYSIS; EUROPE; OVARIAN NEOPLASMS; QUESTIONNAIRE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; EUROPE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84938549042     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.22     Document Type: Article

References (51)

1. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932): 1250-1254.
2. American Cancer Society (2014) http://www.cancer.org/cancer/ovariancancer/ detailedguide/ovarian-cancer-survival-rates.
3. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, Kjaer SK (2013) Non-steroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92(3): 245-255.
4. Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5): 748-758.
5. Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies. Biometrics 46(3): 813-826.
6. Beral V. Million Women Study CollaboratorsBull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574): 1703-1710.
7. Braem MG, Onland-Moret NC, Schouten LJ, Kruitwagen RF, Lukanova A, Allen NE, Wark PA, Tjønneland A, Hansen L, Braüner CM, Overvad K, Clavel-Chapelon F, Chabbert-Buffet N, Teucher B, Floegel A, Boeing H, Trichopoulou A, Adarakis G, Plada M, Rinaldi S, Fedirko V, Romieu I, Pala V, Galasso R, Sacerdote C, Palli D, Tumino R, Bueno-de-Mesquita HB, Gram IT, Gavrilyuk O, Lund E, Sánchez MJ, Bonet C, Chirlaque MD, Larrañaga N, Gurrea AB, Quirós JR, Idahl A, Ohlson N, Lundin E, Jirström K, Butt S, Tsilidis KK, Khaw KT, Wareham N, Riboli E, Kaaks R, Peeters PH (2012) Multiple miscarriages are associated with the risk of ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition. PLoS One 7(5): e37141.
8. Buuren S, Groothuis-Oudshoorn K (2013) MICE: multivariate imputation by chained equations in R. J Stat Softw 45.
9. Collaborative Group on Epidemiological Studies of Ovarian Cancer Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609): 303-314.
10. Collett D (2003) Modelling survival data in medical research. 2nd edn (Chapman & Hall/CRC: Florida, USA.
11. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ (1983) Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71(4): 711-716.
12. Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, Webb PM, Jordan SJ. Australian Cancer Study (Ovarian Cancer)Australian Ovarian Cancer Study GroupRossing MA, Doherty JA, Lurie G, Thompson PJ, Carney ME, Goodman MT, Ness RB, Modugno F, Edwards RP, Bunker CH, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Cramer DW, Terry KL, Vitonis AF, Bandera EV, Olson SH, King M, Chandran U, Kiemeney LA, Massuger LF, van Altena AM, Vermeulen SH, Brinton L, Wentzensen N, Lissowska J, Yang HP, Moysich KB, Odunsi K, Kasza K, Odunsi-Akanji O, Song H, Pharaoh P, Shah M, Whittemore AS, McGuire V, Sieh W, Sutphen R, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Risch HA, Jensen A. Ovarian Cancer Association Consortium (2013) Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control 24(5): 989-1004.
13. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403.
14. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, Trichopoulos D, Beral V (1991) Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 49(1): 57-60.
15. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Harnack L, Hankinson SE, Larsson SC, Leitzmann M, McCullough ML, Marshall J, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Wolk A, Zhang SM, Smith-Warner SA (2006) Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer 94(5): 757-762.
16. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109: 221-227.
17. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL (2013) Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 132(12): 2894-2900.
18. Greiser CM, Greiser EM, Doren M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5): 453-463.
19. Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM (2014) The relation between endometriosis and ovarian cancer-A review. Acta Obstet Gynecol Scand 93(1): 20-31.
20. Hippisley-Cox J, Coupland C (2012) Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 344: d8009.
21. Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control 23(6): 919-927.
22. Kazerouni N, Greene MH, Lacey Jr JV, Mink PJ, Schairer C (2006) Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer 107(5): 1075-1083.
23. Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Köbel M, Lurie G, Thompson PJ, Carney ME, Moysich K, Edwards R, Bunker C, Jensen A, Høgdall E, Cramer DW, Vitonis AF, Olson SH, King M, Chandran U, Lissowska J, Garcia-Closas M, Yang H, Webb PM, Schildkraut JM, Goodman MT, Risch HA. Australian Ovarian Cancer Study Group and Australian Cancer Study (Ovarian Cancer)Ovarian Cancer Association Consortium (2013) Recent alcohol consumtion and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer 13: 28.
24. Lee JY, Jeon I, Kim JW, Song YS, Yoon JM, Park SM (2013) Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 23(3): 402-412.
25. McCaskill-Stevens W, Wilson JW, Cook ED, Edwards CL, Gibson RV, McElwain DL, Figueroa-Moseley CD, Paskett ED, Roberson NL, Wickerham DL, Wolmark N (2013) National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. Clin Trials 10: 280-291.
26. Menon U, Griffin M, Gentry-Maharaj A (2014) Ovarian cancer screening-current status, future directions. Gynecol Oncol 132(2): 490-495.
27. Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL (2013) Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 28(5): 1406-1417.
28. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB (2011) Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 21(3): 188-196.
29. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, Sant M. Eurocare Working Group (2012) Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 51(4): 441-453.
30. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, the Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Webb PM. Ovarian Cancer Association Consortium (2013) Obesity and risk of ovarian cancer types: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20(2): 251-262.
31. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A. Ovarian Cancer Association Consortium (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4): 385-394.
32. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statist Med 23(13): 2109-2123.
33. Pfeiffer RM, Park Y, Kreimer AR, Lacey Jr JV, Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, Hartge P (2013) Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: Derivation and validation from population-based cohort studies. Plos Med 10(7): e1001492.
34. Powell CB (2014) Clinical management of patients at inherited risk for gynecologic cancer. Curr Opin Obstet Gynecol 27(1): 14-22.
35. Quirk JT, Natarajan N, Mettlin CJ (2002) Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol Oncol 99(1): 248-250.
36. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondière UR, Hémon B, Casagrande C, Vignat J, Overvad K, Tjønneland A, Clavel-Chapelon F, Thiébaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-De-Mesquita HB, Peeters PH, Lund E, Engeset D, González CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, Kaaks R, Saracci R (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5(6B): 1113-1124.
37. Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 26(Suppl 1): S6-14.
38. Rice MS, Hankinson SE, Tworoger SS (2014) Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 102(1): 192-198.
39. Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 5(1): 13.
40. Rosner BA, Colditz GA, Webb PM, Hankinson SE (2005) Mathematical models of ovarian cancer incidence. Epidemiology 16(4): 508-515.
41. Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28(5): 964-974.
42. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. Wiley: New York, USA.
43. Shih L, Kurman R (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5): 1511-1518.
44. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ. Australian Cancer Study (Ovarian Cancer)Australian Ovarian Cancer Study GroupGoodman MT, Lurie G, Chang-Claude J, Rudolph A, Kjær SK, Jensen A, Høgdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeney LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS. Ovarian Cancer Association Consortium (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 42(2): 579-589.
45. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM. Australian Cancer Study (Ovarian Cancer)Australian Ovarian Cancer Study GroupRossing MA, Schildkraut J, Risch H, Goodman MT. Ovarian Cancer Association Consortium (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res 6(8): 811-821.
46. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ. Australian Ovarian Cancer Study GroupAustralian Cancer Study (Ovarian Cancer)Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N. Ovarian Cancer Association Consortium (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acertaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106(2): djt431.
47. Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC, Overvad K, Hansen L, Tjønneland A, Rinaldi S, Romieu I, Boutron-Ruault MC, Clavel-Chapelon F, Lukanova A, Boeing H, Schütze M, Benetou V, Palli D, Berrino F, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodríguez L, Duell EJ, Sánchez MJ, Huerta JM, Ardanaz E, Amiano P, Khaw KT, Wareham N, Riboli E (2011b) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22(8): 1075-1084.
48. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjønneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schütze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodríguez L, Travier N, Sánchez MJ, Huerta JM, Ardanaz E, Larrañaga N, Jirström K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E (2011a) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105(9): 1436-1442.
49. USPSTF (2002) Chemoprevention of breast cancer: recommendations and rationale (online). Available at http://www.uspreventiveservicestaskforce.org/3rduspstf/breastchemo/breastchemorr.htm.
50. van Nagell Jr JR, Hoff JT (2013) Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health 6: 25-33.
51. Vergouwe Y, Royston P, Moons KG, Altman DG (2010) Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol 63: 205-214.